Entresto Facing Pressure From Diabetes Drugs

 
• By Lucie Ellis-Taitt
Pressure
SGLT2 inhibitors, already approved for diabetes, could soon disrupt Novartis's Entresto plans in CHF • Source: Shutterstock

More from Cardiovascular

More from Therapeutic Category